CN118159305A - 脱糖基化抗体的放射性复合物和放射性药物 - Google Patents
脱糖基化抗体的放射性复合物和放射性药物 Download PDFInfo
- Publication number
- CN118159305A CN118159305A CN202280071610.3A CN202280071610A CN118159305A CN 118159305 A CN118159305 A CN 118159305A CN 202280071610 A CN202280071610 A CN 202280071610A CN 118159305 A CN118159305 A CN 118159305A
- Authority
- CN
- China
- Prior art keywords
- antibody
- complex
- group
- amino acid
- linker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021-141625 | 2021-08-31 | ||
| JP2021141625 | 2021-08-31 | ||
| PCT/JP2022/032709 WO2023033022A1 (ja) | 2021-08-31 | 2022-08-31 | 脱グリコシル化抗体の放射性複合体、及び、放射性医薬 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118159305A true CN118159305A (zh) | 2024-06-07 |
Family
ID=85411332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280071610.3A Pending CN118159305A (zh) | 2021-08-31 | 2022-08-31 | 脱糖基化抗体的放射性复合物和放射性药物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240316228A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4397320A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JPWO2023033022A1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN118159305A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202325343A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023033022A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2022080481A1 (cg-RX-API-DMAC7.html) * | 2020-10-16 | 2022-04-21 | ||
| CA3215787A1 (en) * | 2021-03-31 | 2022-10-06 | Nihon Medi-Physics Co., Ltd. | Radioactive complex of anti-egfr antibody, and radiopharmaceutical |
| JPWO2022224980A1 (cg-RX-API-DMAC7.html) * | 2021-04-20 | 2022-10-27 | ||
| AU2024234975A1 (en) * | 2023-03-15 | 2025-09-18 | Kagoshima University | Method for producing radiolabeled antibody, radiolabeled antibody, and radiopharmaceutical |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4334141B2 (ja) * | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| JP6872181B2 (ja) | 2015-05-20 | 2021-05-19 | 国立大学法人 鹿児島大学 | IgG結合ペプチドによる抗体の特異的修飾 |
| EP3418304B1 (en) | 2016-02-15 | 2021-08-04 | Kanagawa Prefectural Hospital Organization | Recognition of membrane type mucin-like protein and clinical application thereof |
| DK3470418T3 (da) | 2016-06-13 | 2024-09-30 | Univ Kagoshima | Site-specifik radioisotop-mærket antistof ved brug af using iggbindende peptid |
| WO2018230257A1 (ja) | 2017-06-16 | 2018-12-20 | 国立大学法人鹿児島大学 | IgG結合ペプチド、及び該ペプチドによる抗体の特異的修飾 |
| JP2021506842A (ja) * | 2017-12-18 | 2021-02-22 | ヤンセン バイオテツク,インコーポレーテツド | ポリペプチドの放射性標識 |
| TW202504917A (zh) | 2018-06-21 | 2025-02-01 | 美商再生元醫藥公司 | 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症之方法 |
| ES3075769T3 (en) * | 2019-05-10 | 2026-08-07 | Janssen Biotech Inc | Macrocyclic chelators and methods of use thereof |
| PH12022550894A1 (en) * | 2019-10-18 | 2023-03-27 | Nihon Mediphysics Co Ltd | Ri-labeled humanized antibody |
| CN114555132A (zh) * | 2019-10-18 | 2022-05-27 | 日本医事物理股份有限公司 | 放射性金属标记抗体的制造方法 |
| JP7291797B2 (ja) | 2019-10-18 | 2023-06-15 | 住友ファーマ株式会社 | ヒト化抗体およびその使用方法 |
| JP7680745B2 (ja) | 2019-10-24 | 2025-05-21 | 国立大学法人 鹿児島大学 | 1価ccap生成物の製造方法 |
| JP6827224B1 (ja) | 2020-02-29 | 2021-02-10 | 隆一 嶋田 | 通信回線を利用した電力系統安定化システム |
-
2022
- 2022-08-31 JP JP2023545630A patent/JPWO2023033022A1/ja active Pending
- 2022-08-31 EP EP22864604.8A patent/EP4397320A4/en active Pending
- 2022-08-31 CN CN202280071610.3A patent/CN118159305A/zh active Pending
- 2022-08-31 US US18/688,001 patent/US20240316228A1/en active Pending
- 2022-08-31 TW TW111132932A patent/TW202325343A/zh unknown
- 2022-08-31 WO PCT/JP2022/032709 patent/WO2023033022A1/ja not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| TW202325343A (zh) | 2023-07-01 |
| WO2023033022A1 (ja) | 2023-03-09 |
| EP4397320A4 (en) | 2026-08-12 |
| US20240316228A1 (en) | 2024-09-26 |
| EP4397320A1 (en) | 2024-07-10 |
| JPWO2023033022A1 (cg-RX-API-DMAC7.html) | 2023-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7679326B2 (ja) | Ri標識されたヒト化抗体 | |
| US20240316228A1 (en) | Radioactive complex of deglycosylated antibody and radioactive pharmaceutical product | |
| TW202128732A (zh) | 放射性金屬標定抗體、其製造方法、螯合連接子、及肽修飾抗體 | |
| WO2023277144A1 (ja) | Heg1タンパク質に結合するヒト化抗体および当該抗体と放射性核種との複合体 | |
| US20240189461A1 (en) | Humanised antibodies labelled with radionuclides that emit beta-rays | |
| CN116456992A (zh) | 抗her2抗体的放射性复合物和放射性药物 | |
| EP4327831A1 (en) | Radioactive complex of anti-cd20 antibody, and radiopharmaceutical | |
| US20250152760A1 (en) | Radioactive complex of anti-vegf antibody, and radiopharmaceutical | |
| EP4317188A1 (en) | Radioactive complex of anti-egfr antibody, and radiopharmaceutical | |
| CN117769440A (zh) | 抗cd20抗体的放射性复合物和放射性药物 | |
| EP4230637A1 (en) | Radioactive complexes of anti-her2 antibody, and radiopharmaceutical | |
| CN117377690A (zh) | 抗egfr抗体的放射性复合物和放射性药物 | |
| EA050335B1 (ru) | Радиоактивный комплекс анти-egfr антитела и радиофармацевтическое средство | |
| EA051630B1 (ru) | Радиоактивные комплексы анти-her2 антитела и радиофармацевтическое средство |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |